Filter By Category
Archives
Share on -
AZERUTAMIG
Generic Name: AZERUTAMIG
ABSTRACT -
Azerutamig, also known as DF-1001, is an investigational heterodimeric multi-specific IgG1 antibody designed to engage HER2-expressing tumour cells and immune effector cells, including natural killer/cytotoxic cells through NKG2D and CD16a-related biology. It is being studied as an immune-oncology therapeutic. Because it is a large biologic antibody-like construct, it does not have a simple small-molecule skeletal structure. Development/regulatory status: Investigational.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- No approved routine dosing schedule is established.
- Administration must follow an oncology clinical-trial protocol, commonly by intravenous infusion.
- Dose escalation, premedication, infusion rate, and combination therapy depend on study design and safety findings.
- Do not use outside regulated research or approved specialist care.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Infusion-related reactions, fever, chills, hypotension, or rash
- Cytokine-mediated symptoms such as fatigue, myalgia, nausea, or laboratory inflammation
- Immune-mediated tissue inflammation or organ toxicity
- Cytopenias or infection risk in heavily pretreated oncology patients
- Potential HER2-related on-target/off-tumour toxicity
ALLERGIC REACTIONS -
Hypersensitivity to azerutamig or related compounds/products may occur. Symptoms may include:
- Infusion reaction or injection-site reaction where applicable
- Rash or urticaria
- Bronchospasm or breathing difficulty
- Facial, lip, tongue, or throat swelling
- Anaphylaxis
Important: Patients who develop an allergic reaction to azerutamig should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
- Other immunotherapies may increase immune-mediated toxicity.
- Corticosteroids or immunosuppressants may alter efficacy and toxicity management.
- Myelosuppressive chemotherapy, radiation, or biologics require protocol-specific review.
- Patients should disclose all medicines, supplements, and investigational agents.
PREAUTIONS–
- Administer in centres experienced with immune-oncology infusions and toxicity management.
- Monitor infusion reactions, cytokine symptoms, blood counts, liver enzymes, renal function, and organ-specific symptoms.
- Use caution in active autoimmune disease, uncontrolled infection, or severe cardiopulmonary disease.
WARNINGS –
- Immune-cell engagers can cause serious infusion reactions and immune-mediated toxicity.
- Report breathing difficulty, hypotension, high fever, chest pain, or severe rash immediately.
- Keep out of reach of children.
Share on -
. Developed by